J Gynecol Oncol.  2018 Sep;29(5):e72. 10.3802/jgo.2018.29.e72.

The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients

• Lim S
• Kim YH
• Lee KB
• Lee JM

• KMID: 2417455
• DOI: http://doi.org/10.3802/jgo.2018.29.e72

Abstract

OBJECTIVE
To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients.
METHODS
In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model.
RESULTS
The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p < 0.001). The study group had similar parity (p = 0.71), lower body mass index (p = 0.03) and more premenopausal women (p < 0.001) than the control group. The stages were completely matched. The grades (p = 0.42), lymphovascular space invasion (p = 0.23), preoperative cancer antigen 125 (CA 125) level (p = 0.89), and hormone receptor status (p = 0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p < 0.001). Both group received similar adjuvant therapy (p = 0.80). In the propensity matching, only hormone receptor status was significantly different (p = 0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p = 0.63) and in the OS (p = 0.32) was not significant. The same results were obtained after propensity score matching.
CONCLUSION
Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.

Keyword

Endometrial Neoplasms; Hormone Replacement Therapy; Drospirenone; Estradiol

MeSH Terms

Body Mass Index
Case-Control Studies
Disease-Free Survival
Endometrial Neoplasms*
Estradiol
Female
Gynecology
Hormone Replacement Therapy
Humans
Logistic Models
Mortality
Multivariate Analysis
Obstetrics
Parity
Propensity Score
Recurrence
Retrospective Studies
Survivors
Estradiol